221 results on '"Berno, Tamara"'
Search Results
2. Hospitalization-based epidemiology of systemic and cardiac amyloidosis in the Veneto Region, Italy
3. Chest pain in cardiac amyloidosis: occurrence, causes and prognostic significance
4. When Waldenström macroglobulinemia hits the kidney: Description of a case series and management of a “rare in rare” scenario
5. Dealing With High-Risk AL Amyloidosis Patients: A Single Hematologic Center Experience
6. Is vitamin D deficiency a risk factor for osteonecrosis of the jaw in patients with cancer? A matched case–control study
7. Thromboembolic and Bleeding Events in Transthyretin Amyloidosis and Coagulation System Abnormalities: A Review
8. Waldenström Macroglobulinemia in Very Elderly (≥75-year-old) Patients: A 33-year-retrospective Cohort Study in an Italian University Hospital
9. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI
10. POEMS syndrome associated with IgM lambda paraprotein. A case report and review of the literature
11. P-129 Real world evidence of prognostic impact of t(14;16) translocation in multiple myeloma: a report of the myeloma triveneto working group
12. P1111: WALDENSTRÖM MACROGLOBULINEMIA IN THE VERY ELDERLY (≥75-YEAR-OLD): DESCRIPTION OF CLINICAL FEATURES AND SURVIVAL OUTCOMES IN A CASE SERIES FROM AN ITALIAN ACADEMIC CENTER
13. Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis
14. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
15. Peripheral neuropathy as clinical onset of monoclonal IgM/k‐related amyloidosis
16. Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation
17. Tixagevimab/Cilgavimab as pre-exposure prophylaxis against SARS-CoV-2 in patients with hematological malignancies
18. CK1α/RUNX2 Axis in the Bone Marrow Microenvironment: A Novel Therapeutic Target in Multiple Myeloma
19. 193 Epidemiological trend of amyloidosis and its association with cardiovascular conditions: a single-center report
20. 325 Dealing with cardiac amyloidosis diagnosis: keep calm and use the magnifying glasses!
21. 188 Disarming the bomb in AL amyloidosis: a case report
22. Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
23. Lenalidomide in patients with chemotherapy-induced polyneuropathy and relapsed or refractory multiple myeloma: results from a single-centre prospective study
24. Cardiovascular Complications in Patients with AL Amyloidosis
25. Mechanisms of Thrombosis in Paraproteinemias: The Effects of Immunomodulatory Drugs
26. Effect of time to infusion of autologous stem cells (24 vs. 48 h) after high-dose melphalan in patients with multiple myeloma
27. Low-risk identification in multiple myeloma using a new 14-gene model
28. Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients
29. Light Chain Deposition Disease: First Analysis of an International Study in 359 Patients
30. High rate of profound clonal and renal responses with daratumumab treatment in heavily pre‐treated patients with light chain (AL) amyloidosis and high bone marrow plasma cell infiltrate
31. Lenalidomide for bortezomib-resistant multiple myeloma
32. Treatment with Daratumumab in Patients with Multiple Myeloma Associated AL Amyloidosis
33. Immune Profiling of Plasma Cell Dyscrasias Reveals a Therapy Related T-Cell Modulation in Multiple Myeloma Patients
34. Immunomodulatory drugs in plasma cell diseases: everything has its price
35. Cardiac amyloidosis: a review of the literature and a practical approach for the clinicians
36. Severe infections unrelated to neutropenia impact on overall survival in multiple myeloma patients: results of a single centre cohort study
37. Bortezomib-based regimens in patients with POEMS syndrome: a case series in newly diagnosed and relapsed patients
38. Whole-body low-dose CT recognizes two distinct patterns of lytic lesions in multiple myeloma patients with different disease metabolism at PET/MRI
39. A unique case of rapidly progressive glomerulonephritis following dexamethasone/bortezomib/thalidomide treatment for myeloma
40. Effect of low‐dose bortezomib on bone formation in smouldering multiple myeloma
41. Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: a report of three cases
42. STAT3 mutation impacts biological and clinical features of T-LGL leukemia
43. Diffusion Weighted Whole Body MRI for Evaluation of Early Response in Multiple Myeloma
44. Infections in Multiple Myeloma: An Understimate Risk Factor of Comorbidity
45. Hyperammonemic Encephalopathy as Initial Presentation of Multiple Myeloma
46. Parathyroid hormone receptor mediates the anti-myeloma effect of proteasome inhibitors
47. Lenalidomide long-term neurotoxicity
48. Immunomodulatory drugs in plasma cell diseases: everything has its price.
49. Phenotypic Heterogeneity of Chronic Lymphoproliferative Disorder of NK Cells
50. Rituximab-Bendamustine Cytarabine (R-BAC) As Frontline Therapy in Mantle Cell Lymphoma: A Single-Center Experience
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.